PD-1/PD-L1 blockade-based combination therapies have shown potent antitumor effects but primary resistance as well as acquired resistance and toxic side effects remain problematic and in need of further investigation. Get more information on proposed strategies that aim to improve clinical outcomes of combination therapies in this overview article.
Please check the highlighted fields and try again.
Please enter your first and last name.
Please enter the name of the company or institution you work at.
Please enter your mailing address.
Please enter the e-mail address you would like to be contacted at.